Premium
A retrospective study of the safety and efficacy of low molecular weight iron dextran for children with iron deficiency anemia
Author(s) -
Boucher Alexander A.,
Bedel Ashley,
Jones Sommer,
Lenahan Stephanie F.,
Geer Rebecca,
McGann Patrick T.
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.29024
Subject(s) - medicine , dosing , anemia , adverse effect , retrospective cohort study , pediatrics , ferritin , incidence (geometry) , hemoglobin , iron deficiency , nomogram , iron deficiency anemia , surgery , physics , optics
Background Iron deficiency anemia (IDA) affects millions of children worldwide. Oral iron replacement is effective but often poorly tolerated. Intravenous iron has been demonstrated to have utility in all ages, but pediatric use remains limited. Low molecular weight iron dextran (LMWID) has a dosing range capable of replacing iron deficits in a single infusion and has been evaluated in small pediatric cohorts, but additional safety and efficacy data are limited. Here, we evaluate the safety and efficacy of LMWID in association with an electronic medical record (EMR)‐based effort to optimize dosing. Procedure A retrospective IRB‐approved investigation of LMWID utilization at a tertiary pediatric hospital between January 1, 2016 and March 31, 2020 was undertaken to evaluate the therapeutic efficacy and frequency/severity of infusion‐related adverse event (AE) in children and adolescents receiving LMWID. Patient demographics and LMWID dosing characteristics were collected, and primary outcome measures included laboratory response and the incidence/severity of any infusion‐related events. The utilization of an EMR‐based nomogram for LMWID dosing was also evaluated. Results A total of 254 infusions for 191 patients were included (ages 0.7–20.9 years), most with IDA. LMWID replaced at least 75% of the estimated iron deficit in a single infusion for 76% of patients. The mean hemoglobin and ferritin increases were 2.1 g/dl and >100 ng/ml, respectively. Infusion‐related AEs were rare, occurring in only 12/254 (4.7%) of infusions and 67% during the test dose; each rapidly resolved without long‐term sequelae. No AEs occurred in those <10 years of age. Premedication use markedly decreased with nomogram use without a change in AE rate. Conclusions In a large institutional cohort, LMWID was well tolerated in children and adolescents, with most patients having their total iron deficits relieved in a single infusion. These data support expanded use of LMWID in the management of pediatric iron deficiency.